Is life worth living?
It all depends on the
liver
LIVERFASt™
for NAFLD, NASH,
HCV, HBV, Cirrhosis
& Hepatocellular
Carcinoma.
Uniquely Position among Non-invasive technologies
A single blood draw diagnostic powered by Artificial intelligence
on broadly available biomarkers that provides equivalence to a biopsy.
Patent Technology
CPT Code: 0166U
FDA – De Novo 510K
CLIA Certified
Artificial Technology based Platform
LIVERFASt™ has now been granted CPT Code.
The American Medical Association (AMA) and The Centers for Medicare & Medicaid Services (CMS) awarded LIVERFASt™ a CPT Code with the highest reimbursement fee in its category!
Learn More
Complete Liver Diagnosis
LIVERFASt™ – from Early Stage to Late Stage
for NAFLD , NASH Cirrhosis & Hepatocellular Carcinoma.
Diagnosis
Non-invasive disease detection means earlier diagnosis and earlier intervention for better patient outcomes.
Screening
Risk stratification among large patient populations allows for better management leading to cost reductions.
Monitoring
Regular surveillance with easily repeatable non-invasive diagnostics enables optimized disease management.
for NAFLD , NASH Cirrhosis & Hepatocellular Carcinoma.
Diagnosis
Non-invasive disease detection means earlier diagnosis and earlier intervention for better patient outcomes.
Screening
Risk stratification among large patient populations allows for better management leading to cost reductions.
Monitoring
Regular surveillance with easily repeatable non-invasive diagnostics enables optimized disease management.
X
Fibronostics Appoints Dr. Stephen A. Harrison to its Board of Advisors
